Johnson & Johnson's combined therapy JNJ-4804 for inflammatory bowel disease did not meet its primary endpoint despite showing better performance than individual drugs. This development is crucial for tech professionals and developers as it underscores the complexity of immune system modulation in IBD, potentially guiding future research towards more targeted patient subgroups.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



